Compare T Rowe Price Group Inc (TROW) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs Zoetis Inc — how do they compare? T Rowe Price Group Inc trades at $111.15 (market cap $24.26B), while Zoetis Inc trades at $72.57 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays the higher dividend (4.57%). Which is the better fit depends on your goals.
| TROW | ZTS | |
|---|---|---|
Market Cap | $24.26B | $31.14B |
Sector | Financials | Health |
52-Week High | $121.68 | $156.76 |
52-Week Low | $86.19 | $71.91 |
Enterprise Value | $21.46B | $38.70B |
Dividend Yield | 4.57% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price (TROW) trades at $111.17, down 2.29% on the day, with a bearish technical signal driven by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $2.57, supported by record assets under management. Revenue and net income have shown steady growth, with 2025 revenue at $7.31B and net income at $2.09B. The company maintains strong profitability, with a net margin of 29.26% and ROE of 20.1%. Valuation ratios appear reasonable, with a P/E of 11.42 and EV/EBITDA of 6.75. Dividends remain consistent, with a recent quarterly payment of $1.30 declared.
The outlook for TROW is mixed; fundamental strength from earnings growth and solid cash flow supports potential upside, but technical bearishness and analyst caution pose near-term risks. Investment opportunity lies in its undervalued metrics and dividend reliability, while risks include expense pressures and market volatility affecting asset flows. The consensus price target of $112.17 suggests limited upside from current levels, emphasizing a hold stance amid balanced factors.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
